Paragon Care Limited Overview
| Field | Detail | Source |
|---|---|---|
| Legal name | Paragon Care Limited | FY26 Appendix 4E |
| Trading name | ParagonCare | FY25 Annual Report |
| ABN / ACN | ABN 76 064 551 426 / ACN 064 551 426 | FY26 Appendix 4E; 1H26 Investor Presentation |
| Former names | Not publicly disclosed in reviewed sources (no formal name change identified) | — |
| Founding year (legacy Paragon Care) | 2008 (company "About" page) | paragoncare.com.au |
| Founding year (CH2 / Clifford Hallam lineage) | 1918 ("We started out in Australia in 1918") | FY25 Annual Report |
| Incorporation jurisdiction | Australia (Corporations Act 2001) | FY25 Annual Report, Note 1 |
| Registered office & principal place of business | 77–97 Ricketts Road, Mount Waverley, VIC 3149, Australia | FY25 Annual Report, Note 1 |
| Exchange / ticker | Australian Securities Exchange — PGC (secondary listing: Deutsche Börse ticker PXS, per Fintel) | ASX; Fintel |
| ISIN | AU000000PGC4 | Fintel |
| CUSIP | Not applicable / not publicly disclosed (Australian issuer) | — |
| Fiscal year end | 30 June | Annual reports |
| Employees | 1,292 (FY25); "over 1,200" cited in FY25 Chair/CEO letter; FY24 and FY23 combined-group figures not publicly disclosed | FY25 Annual Report |
| Gender split (FY25) | 51% male / 49% female | FY25 Annual Report |
| Auditor | Ernst & Young (Melbourne; FY25 lead partner Paul Gower) | FY25 Annual Report; FY26 Appendix 4E |
| Share registry | Not re-verified for FY26 (FY22: Link Market Services) | FY22 Annual Report |
| Shares on issue | 1,655,305,389 (weighted average FY25 and FY26; ~1.66bn) | FY26 Appendix 4E, Part 17 |
| Share price (latest verified) | A$0.135 (4 Sep 2026); A$0.13–0.135 range Jul–Sep 2026. | InvestSMART |
| Market capitalisation | ≈A$223m at A$0.135 (1,655.3m shares) | InvestSMART; calculation |
| CEO & MD | Carmen Riley (CEO from 1 Jul 2025; MD from 1 Mar 2026) | ASX announcements 25 Jun 2025, 25 Feb 2026 |
| Chair | Peter Lacaze | FY25 Annual Report |
| Website | https://www.paragoncare.com.au | — |
The entity on the user's list (Paragon Care Limited, ASX: PGC, Australia) remains the same listed legal entity. Its trading name is now styled "ParagonCare". The website on the list (paragoncare.com.au) is current. No change of ticker or exchange has occurred. The economic business, however, is now dominated by the former Clifford Hallam Healthcare (CH2) pharmaceutical wholesale business following the June 2024 reverse acquisition.
ParagonCare is a mid-sized, founder-controlled Asia-Pacific healthcare distributor that combines a high-volume, thin-margin Australian pharmaceutical wholesale engine (inherited from Clifford Hallam Healthcare, Australia's only independent Community Service Obligation wholesaler) with a portfolio of higher-margin specialty businesses: medical technology agencies (imaging, devices, orthopaedics, robotics, vision, aesthetics, dental), third-party healthcare contract logistics, and TGA-certified clinical manufacturing of red-cell blood-bank reagents. FY26 revenue was A$3.68bn, but underlying EBITDA of A$97.2m represents a margin of only ~2.6%, and 96% of revenue still comes from Australia and New Zealand. Strategy is pivoting toward Asia, where six bolt-on acquisitions in FY26 lifted segment revenue 58% to A$160m at ~42% gross margin. The equity story is constrained by a A$38.0m credit loss on the collapsed Infinity Pharmacy Group, a statutory FY26 loss, leverage of ~2.5x, negative net tangible assets, no dividend, and a share price that has fallen roughly 60–70% from its post-merger implied level.
Company's own description
The FY25 Annual Report and FY26 Appendix 4E describe ParagonCare as one of Asia Pacific's leading diversified healthcare distributors and manufacturers, delivering pharmaceuticals, capital equipment, diagnostics, medical consumables, devices and complementary medicines, with origins in Australia in 1918 and a "transformational" 2024 merger of Clifford Hallam and ParagonCare. Its stated purpose is to make healthcare simpler, smarter and more accessible across Asia Pacific, and its vision is to be the region's most trusted and efficient diversified healthcare distribution and manufacturing partner (FY25 Annual Report).
The statutory principal-activities description (FY25 Directors' Report; FY26 Appendix 4E Part 8) is: supply of durable medical equipment, medical devices, consumable medical products and maintenance of technical medical equipment to the health, aged care (and aesthetics/veterinary) markets throughout Australia, New Zealand and Asia, plus distribution of pharmaceuticals, medical consumables and complementary medicines to the Australian healthcare market.
Go-to-market structure (four channels)
| Channel | Business units | Core customers |
|---|---|---|
| Wholesale | Pharmacy; Medical Consumables; Complementary Medicines (Oborne, ParagonCare Prescribe); Dental Supplies (incl. AHP Dental) | Independent retail pharmacies, non-affiliated and affiliated pharmacy groups (incl. second-line wholesaling), public and private hospitals, aged care, primary care, allied health, naturopaths/TCM practitioners, dental clinics |
| Medical Technology | OEM Capital (imaging, PACS); OEM Devices (infusion, oncology, neonatal, surgical, critical care, urology); Vision; Aesthetics; Surgical Implants/Orthopaedics; Surgical Robotics (CMR Surgical); Service | Public/private hospitals, day surgeries, orthopaedic surgeons, optometrists/ophthalmologists, dermatologists/cosmetic clinics, imaging departments |
| Contract Logistics | 3PL/4PL services for healthcare suppliers (e.g., Owens & Minor from June 2025; Pacific Medical in Hong Kong from Feb 2026) | Pharmaceutical and medtech manufacturers, public health distribution centres, pharmaceutical wholesalers |
| Clinical Manufacturing | Immulab red-cell reagent manufacturing; contract manufacturing (first agreement FY25); diagnostic instruments & consumables distribution; Fisher Biotec (acquired Jan 2026) | Pathology labs, blood banks, IVF clinics, microbiology labs, universities, hospitals |
Following a FY25 restructuring, the group operates through four go-to-market channels supported by shared services (Finance, IT, Marketing, Customer Service, Supply Chain, Commercial, Procurement):
(Source: FY25 Annual Report, "Business Focus" and "Customer Networks" pages; FY26 Results Release.)
Revenue model and value-chain position
| Revenue type (AUD Mn) | FY25 | FY26 |
|---|---|---|
| Goods (point in time) | 3,580.1 | 3,652.3 |
| Services (over time) | 33.8 | 28.3 |
| Total revenue | 3,613.9 | 3,680.5 |
| Supplier rebates (memo) | 417.2 | 450.9 |
The revenue model is overwhelmingly product resale (point-in-time recognition). In FY26, goods transferred at a point in time were A$3,652.3m (99.2%) and services transferred over time were A$28.3m (0.8%), versus A$3,580.1m and A$33.8m in FY25 (FY26 Appendix 4E, Part 9). There is no material subscription or licensing revenue. Supplier rebates are a critical economic lever: rebates of A$450.9m in FY26 (A$417.2m in FY25) offset a gross cost of inventories sold of A$3,787.8m, meaning rebates are larger than the group's entire gross margin (A$347.5m) (FY26 Appendix 4E, Part 9b).
ParagonCare sits in the mid-stream distribution layer of the healthcare value chain: it buys from originator and generic pharmaceutical manufacturers, global medtech OEMs (for which it often holds exclusive regional agency rights) and private-label sources, and sells to pharmacies, hospitals and clinics. Upstream, it manufactures a narrow line of in-vitro diagnostic reagents (Immulab) and offers contract manufacturing. Sideways, it monetises its warehouse network by providing contract logistics to other suppliers.
Independent characterisation
Economically, ParagonCare is two businesses wearing one ticker:
-
A scale-dependent ANZ pharmaceutical and consumables wholesaler (Wholesale channel ≈A$3.0bn of FY25 revenue, ≈82% of group) operating at a channel margin of ~6.0–6.3% (FY26 Results Release) and ANZ segment margin of ~8.0%, competing against far larger incumbents (EBOS/Symbion, Sigma/Chemist Warehouse, Wesfarmers Health/API). This business generates revenue mass, supplier rebates and CSO funding but very little operating profit after warehouse, freight and finance costs.
-
A specialty distribution and manufacturing portfolio (MedTech ~39–41% channel margin, Clinical Manufacturing ~44–46%, Asia ~42–46%) that likely produces the majority of group gross profit dollars outside wholesale, and which is the explicit focus of capital allocation.
The credit event with Infinity Pharmacy Group (a Priceline franchisee) illustrates the principal structural risk of the wholesale model: very large receivable exposures to individual pharmacy groups relative to the group's thin equity cushion.
End-markets served
Retail community pharmacy (independent and banner groups), hospital pharmacy (public and private), acute hospitals (capital, devices, implants), aged care and community care, primary care and allied health, dental, aesthetics/dermatology, optometry/ophthalmology, pathology/blood banking, IVF, defence (5-year Australian Defence Force supply contract from Q4 FY26), and B2B logistics for healthcare manufacturers. Geographic end-markets: Australia, New Zealand, Thailand, South Korea, Japan, Philippines, Vietnam, and (via FY26 acquisitions) Singapore, Malaysia, Indonesia, Hong Kong/Macau. The 1H26 presentation cites a presence in nine Asian countries.
Strategy
Stated strategy themes
"3-2-1" (three businesses, two years, one team): the integration programme for ParagonCare, CH2 and Oborne, declared complete in FY26 with synergies "in line with strategy". The 1H26 release targeted A$12m of synergy benefits by FY26 (after A$5m targeted in FY25).
Strategic positioning statements (FY25 AR): be the leading independent wholesaler and distributor in APAC; be the master franchise holder for APAC agency arrangements; be the best-in-class red-cell diagnostics manufacturer in APAC; offer specialist contract logistics with an integrated service model.
Values: Accountable, Discipline, Empowerment, Initiating, Communication.
FY27 priorities (FY26 Results Release outlook)
| Pillar | Initiatives |
|---|---|
| Geographic & market expansion | Grow Asia regional presence; leverage acquired businesses; enter new markets; expand aesthetics, dental and animal health; launch NZ wholesale channel; strategic M&A |
| Growth initiatives | Product expansion and capability-led organic growth; profitable-revenue focus; enhanced go-to-market; new website and digital marketing; new supplier agreements |
| Operational excellence | Sydney warehouse strategic review (new site FY28); offshoring ANZ administration to Asian shared-service offices; technology investment |
| Capital management | Employee Share Trust to offset EIP dilution; share buyback to commence in FY27; dividend review at 1H27 results |
Initiatives in the last 24 months
| Date | Initiative | Type |
|---|---|---|
| FY25 | Restructure into four channels with shared services | Transformation |
| FY25 | JDE ERP migration of Oborne, DFV, REM, WBM, SMS, Surgical Specialties | Platform |
| May 2025 | Dental BU launch (ANZ) | New business |
| FY25 | Aesthetics BU launch in ANZ (Classys, Neauvia) | New business |
| FY25–FY26 | Surgical robotics entry with CMR Surgical | New business / partnership |
| FY25 | First contract-manufacturing agreement at Mount Waverley | New business |
| Jun 2025 | Owens & Minor 4PL contract | Contract win |
| Jun 2025 | Refinancing: A$325m DFF + A$75m ABF | Capital |
| FY25 | Seven sites consolidated | Cost |
| FY25–FY26 | Brisbane automated DC | Platform |
| FY26 | Regional Asian management team and multi-disciplinary shared services | Transformation |
| Jan 2026 | Exit of low-margin Ramsay contract | Portfolio pruning |
| FY26 | Six Asian/ANZ acquisitions (see Section 11) | M&A |
| Q4 FY26 | Australian Defence Force 5-year contract | Contract win |
| FY27 | Buyback, Employee Share Trust | Capital management |
ESG commitments
Net zero by 2050 ambition; solar programme for warehouses in development; CSR policy (2022); Modern Slavery statement and supplier questionnaire (FY25 AR).
Medium-term targets and guidance
| Item | Detail |
|---|---|
| FY26 guidance (given Feb 2026) | Revenue A$3.6–3.7bn; underlying EBITDA A$97–107m — revenue achieved (A$3.68bn); EBITDA at bottom of range (A$97.2m) |
| FY27 guidance | Not provided "due to economic instability"; expectation of mid-single-digit revenue growth |
| Leverage | FY26 year-end target of 2.5x net debt / underlying EBITDA (incl. LTM of acquisitions) met |
| Medium-term financial targets | — |
Products & Services
Pricing models are not publicly disclosed for any product line; the company acts largely as a reseller or exclusive agent at negotiated contract prices (hospital tenders, pharmacy trading terms, PBS-regulated pricing for prescription medicines).
Wholesale channel
| Offering | Description & capabilities | Target customer | Notes / flagship |
|---|---|---|---|
| Pharmacy wholesale (CH2) | Full-line pharmaceutical wholesaling including PBS medicines; member of Commonwealth CSO and NDSS funding pools | Independent pharmacies, banner groups, hospital pharmacies | Described as Australia's only independent CSO wholesaler (FY25 AR); total pharmacy sales ≈A$2.8bn in FY25 (+11.6%) |
| Vantage program | Low-cost wholesale plus centralised technology platform for independent pharmacies | Independent pharmacies | Grew to service more than 500 pharmacies in FY25 |
| Hospital pharmacy supply | First-line and second-line wholesale to hospitals | Public and private hospitals | Market-share gains in FY25 incl. a first-line partnership; Ramsay contract exited Feb 2026 |
| Medical Consumables (incl. Specialist Medical Supplies) | Broad consumables range including private-label lines | Aged care, community and primary care, allied health, dental | Integrated onto JDE ERP in FY25; ordering via CH2 Direct e-commerce |
| CH2 Direct | B2B e-commerce ordering platform | All wholesale customers | Digital procurement access |
| Complementary Medicines (Oborne Health Supplies) | Distribution of vitamins, herbal/natural medicines, nutrition | Practitioners, naturopaths, TCM, pharmacies, retail | Adelaide and Newcastle footprint added FY25 |
| ParagonCare Prescribe | Practitioner prescribing and direct-to-patient delivery of therapeutic goods | Integrative practitioners and patients | Relaunched FY25 |
| Dental Supplies (incl. AHP Dental & Medical, Presidental) | Dental consumables and equipment; AHP carries 7,000+ products from 50+ brands to 2,500+ customers | Private dental clinics, corporate dental groups, teaching institutions | BU launched May 2025; AHP acquired Jul 2025 |
| NZ wholesale | Pharmac-listed consumables; strategic supplier to largest NZ private hospital group | NZ public and private hospitals | NZ wholesale channel launch flagged for FY27 |
| Defence supply | 5-year Australian Defence Force supply contract | Australian Defence Force | Commenced Q4 FY26; annual value ~A$40m per one aggregator |
Medical Technology channel
| Offering | Description & capabilities | Target customer | Notes / flagship brands (as disclosed) |
|---|---|---|---|
| OEM Capital – imaging | Ultrasound, radiology, surgical and molecular imaging, AI solutions, PACS | Hospital imaging departments, private practice | Samsung ultrasound (NZ clinical support); Carestream; new imaging agreements in Philippines and Japan; retrofit digital solutions in Japan |
| OEM Devices – infusion | Ambulatory and home infusion | Hospital-in-the-home, regional anaesthesia, home parenteral nutrition | Avoset Infusion System launched FY25; >250 Sapphire MT pumps deployed nationally for HPN |
| OEM Devices – oncology | Closed-system drug transfer devices (CSTD) | Hospital oncology/pharmacy | Claimed national CSTD leadership; NSW share gains |
| OEM Devices – neonatal | NICU camera monitoring, phototherapy, newborn hearing screening | Neonatal units | AngelEye NICU video camera introduced FY25 |
| OEM Devices – vascular access, critical care, surgical, urology | Consumable and device portfolios | Acute hospitals | Vietnam catheter fixation expansion FY26 |
| Surgical robotics | Robotic-assisted soft-tissue surgery | ANZ hospitals | CMR Surgical partnership; entry FY26 |
| Orthopaedics / surgical implants | Joint replacement implants, navigation/robotics, orthobiologics | Orthopaedic surgeons, hospitals, day surgeries | Corin second-generation knee robotics launched in NZ; renewed exclusive agreements in Australia; orthobiologics relocated to Eastern Creek |
| Vision (Designs for Vision) | Ophthalmic diagnostics and surgical equipment | Optometrists, ophthalmologists, day surgeries, universities | Surgical and diagnostic vision combined under one leadership in FY25; FY26 headwinds from OEMs going direct |
| Aesthetics | Energy-based devices (HIFU, monopolar RF, microneedle RF), injectables/fillers, skin boosters, cosmeceuticals | Clinics, dermatologists, cosmetic surgeons | Classys devices and Neauvia injectables in ANZ; >40% HIFU share in Vietnam (company claim); Haju Medical (Indonesia/Korea buying house) acquired Apr 2026 |
| Service & Technology | Equipment management, repair and maintenance, OEM service representation, telecommunications, access control, nurse-call/patient monitoring | Hospitals and healthcare facilities | Image Space (NZ capital service) acquired FY25; service revenue declining structurally (HY25/FY25 releases) |
| Asia medtech distribution (Quantum, Somnotec, Pacific Medical, Transpacific) | Imaging, interventional cardiology, oncology, sleep/respiratory and other device distribution | Hospitals in SE/North Asia | Korea: innovative surgical table, endoscopy consumables; Thailand: Good Distribution Practice preparation |
Clinical Manufacturing channel
| Offering | Description & capabilities | Target customer | Notes |
|---|---|---|---|
| Immulab reagent red cells | Manufacture of in-vitro diagnostic red-cell reagents for blood-group serology | Blood banks, pathology labs, hospitals | Supports Australia's self-sufficiency in blood screening reagents; key supply agreement renewed FY25 |
| Contract manufacturing | Third-party manufacturing at TGA-certified Mount Waverley facility | IVD/medical manufacturers | First agreement signed FY25 |
| Diagnostics distribution | Diagnostic instruments and consumables | Pathology, IVF, microbiology, universities | New specialised-diagnostics partnerships FY25 |
| Fisher Biotec | Molecular biology/laboratory products (acquired 30 Jan 2026) | Laboratories | Drove double-digit channel growth in FY26 |
Contract Logistics channel
| Offering | Description & capabilities | Target customer | Notes |
|---|---|---|---|
| 3PL/4PL healthcare logistics | Warehousing, temperature-controlled storage, S8 secure storage, distribution | Global pharma/medtech suppliers, public health DCs, wholesalers | Owens & Minor 4PL from June 2025; >98% on-time delivery for key pharmaceuticals (company claim); team doubled in FY25 |
| Hong Kong/Macau logistics (Pacific Medical / MD Medical Logistics) | Contract logistics plus OEM agencies in interventional cardiology and oncology | HK/Macau hospitals and suppliers | Acquired Feb 2026 |
Legacy Paragon brand inventory
Brands historically operated by legacy Paragon Care (IBISWorld/company listings): Designs for Vision, Electro Medical Group, Immulab, Immuno, Insight Surgical, LabGear, Lovell Surgical Solutions, Meditron, MedTech Solutions, Medtek, Quantum Healthcare, REM Systems (medical and veterinary), Scanmedics, Specialist Medical Supplies, Surgical Specialties, Total Communications, Western Biomedical. Several have been integrated into the JDE ERP and channel structure (Oborne, Designs for Vision, REM Australia, WBM, SMS and parts of Surgical Specialties in FY25).
Financial Narrative
Basis: FY24–FY26 are statutory (FY26 Appendix 4E; FY25 Annual Report). FY22–FY23 are CH2-predecessor figures from stockanalysis.com (aggregator; not reconciled to a primary filing) and are flagged. Blank cells = not publicly disclosed or not verifiable. All figures A$m unless stated.
Income statement
FY24 underlying EBITDA of A$53.0m is the statutory-basis normalisation; the company's FY24 pro-forma (full year of all three businesses) figures were revenue A$3,336.3m and underlying EBITDA A$92.4m (FY25 Results Release). FY24 dividends of A$12.6m were paid by CH2 to its pre-merger owners, not to PGC shareholders.
Margins and growth
Revenue CAGR FY22–FY26: ≈21.2% (A$1,708m → A$3,680.5m), overwhelmingly acquisition- and merger-driven. On the company's pro-forma basis, FY24→FY26 growth is ≈5.0% p.a. (A$3,336m → A$3,681m), and normalised organic growth in FY26 was 6.7%.
Underlying-to-statutory EBITDA bridge
(FY26 Appendix 4E Part 2; FY25 Annual Report Directors' Report.) Gross ECL expense recognised in FY26 was A$38.0m (A$47.3m in 1H26 less a A$9.3m reversal in 2H26), shown net of A$3.1m recoverable GST as A$34.9m in the bridge.
Balance sheet
FY23 equity of A$18.9m is CH2's opening equity at 1 July 2023 (FY25 AR statement of changes in equity). The negative statutory working capital reflects classification of the debtor finance facility as current (going-concern note); company-defined NWC includes A$22.2m deferred consideration and is shown net of the A$39.2m Infinity ECL.
Ratios (calculated by analyst from statutory data)
FY24 ratios are distorted by the reverse-acquisition basis (12 months of CH2 revenue against a year-end balance sheet that includes all of legacy Paragon). Underlying ROIC for FY25 uses underlying EBITDA 95.2 less D&A 29.8.
Commentary on trends, inflections and drivers
Revenue. The step-changes in FY23–FY25 reflect CH2's own growth and acquisitions (Oborne) followed by the merger. FY26 is the first "clean" comparison and shows only 1.8% headline growth because roughly A$230m of annualised Ramsay revenue and the residual Infinity revenue fell away; normalised organic growth of 6.7% and like-for-like-currency underlying EBITDA growth of 7.4% indicate the core is growing, but from a low-margin base.
Gross margin inflection. Gross margin rose from ~6% to 9.4% because the merger added higher-margin specialty businesses and because low-margin wholesale contracts (Ramsay) were exited. This mix shift is the most important positive trend in the numbers.
Operating leverage is negative. Despite gross profit growing A$23.5m in FY26, warehousing and distribution costs rose A$8.8m (fuel and outside-storage costs ahead of the delayed Brisbane DC), employee costs rose A$10.8m, and administration costs more than doubled (driven by the A$38.3m ECL line, but other corporate costs also rose from A$7.3m to A$14.8m and advertising from A$10.7m to A$12.7m). D&A rose 24.9% as acquired supplier-contract intangibles were amortised faster and right-of-use assets grew with the new DC.
Finance costs are the binding constraint. Finance costs of A$35.2m consume more than one-third of underlying EBITDA; interest on bank borrowings alone was A$23.0m, plus A$7.7m of merchant and other finance charges. With the facilities priced at BBSY + 3.05%, every 100bp of base-rate movement on ~A$290m of drawn bank debt is worth roughly A$2.9m pre-tax.
Balance sheet quality is weakening. Equity fell A$34.0m in FY26 (loss plus A$19.4m FX translation loss), goodwill and intangibles rose A$54.2m on acquisitions, and NTA per share deteriorated to −8.59 cents. Vendor contingent consideration rose from A$4.1m to A$56.0m, a deferred cash claim not included in reported net debt. Market capitalisation fell below book value at 30 June 2026, which the company treated as an impairment indicator, but its value-in-use test (FY27–FY31 plan) showed headroom.
Cash flow is recovering but thin. OCF improved to A$29.1m (+317% vs the A$7m pro-forma-type comparison cited by the company; statutory swing from −A$13.4m), but after A$33.2m of capex (mainly the Brisbane DC) free cash flow was still negative, and A$51.4m of acquisitions were debt-funded.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 1,708 | 2,187 | 2,969.9 | 3,613.9 | 3,680.5 |
Revenue growth (%) | 5.6 | 28.0 | 35.8 | 21.7 | 1.8 |
Gross profit (AUD Mn) | 110.9 | 131.4 | 176.5 | 324.0 | 347.5 |
Operating income / EBIT (AUD Mn; FY24–26 = PBT + finance costs) | 18.1 | 29.1 | 29.8 | 58.6 | 13.5 |
Statutory EBITDA (AUD Mn; FY22–23 aggregator definition) | 21.9 | 33.5 | 44.5 | 88.5 | 50.8 |
Underlying EBITDA (AUD Mn; company) | — | — | 53.0 | 95.2 | 97.2 |
Pre-tax income (AUD Mn) | 10.9 | 18.4 | 13.8 | 25.5 | -21.7 |
Net income (AUD Mn) | 7.6 | 12.8 | 8.2 | 20.6 | -16.0 |
Underlying NPAT (AUD Mn; company) | — | — | — | 31.2 | 26.0 |
EPS basic (A cents) | — | — | 0.87 | 1.24 | -0.97 |
EPS diluted (A cents) | — | — | 0.87 | 1.24 | -0.97 |
Dividends per share (A cents) | — | — | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Gross margin (%) | 6.50 | 6.01 | 5.94 | 8.97 | 9.44 |
Operating (EBIT) margin (%) | 1.06 | 1.33 | 1.00 | 1.62 | 0.37 |
Statutory EBITDA margin (%) | 1.28 | 1.53 | 1.50 | 2.45 | 1.38 |
Underlying EBITDA margin (%) | — | — | — | 2.63 | 2.64 |
Net margin (%) | 0.44 | 0.58 | 0.28 | 0.57 | -0.44 |
Financial Analysis
| Item | FY25 | FY26 |
|---|---|---|
Statutory EBITDA | 88.5 | 50.8 |
Infinity provision (net of GST) | 0.0 | 34.9 |
M&A and related costs | 0.0 | 4.7 |
Restructuring and integration | 2.8 | 6.4 |
FX hedges / currency remeasurement | 3.9 | -1.6 |
Share-based payments | 0.0 | 1.9 |
Underlying EBITDA | 95.2 | 97.2 |
Balance Sheet and Per-Share Data
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Total assets (AUD Mn) | — | 1,150.6 | 1,243.7 | 1,373.4 |
Cash & equivalents (AUD Mn) | — | 19.9 | 20.3 | 23.7 |
Borrowings – current (AUD Mn) | — | 106.7 | 160.4 | 222.6 |
Borrowings – non-current (AUD Mn) | — | 89.9 | 76.4 | 85.2 |
Total borrowings (AUD Mn) | — | 196.6 | 236.7 | 307.7 |
Net debt ex-leases (AUD Mn) | — | 176.6 | 216.4 | 284.1 |
Lease liabilities (AUD Mn) | — | 54.5 | 55.6 | 81.2 |
Vendor conditional payables (AUD Mn) | — | 4.2 | 4.1 | 56.0 |
Total equity (AUD Mn) | 18.9 | 291.7 | 329.8 | 295.9 |
Goodwill & intangibles (AUD Mn) | — | 389.2 | 395.5 | 449.7 |
Inventories (AUD Mn) | — | 270.4 | 282.5 | 342.1 |
Trade & other receivables – current (AUD Mn) | — | 346.0 | 401.5 | 370.7 |
Trade & other payables (AUD Mn) | — | 553.5 | 575.8 | 601.2 |
Statutory working capital (current assets less current liabilities, AUD Mn) | — | -24.7 | -14.0 | -104.8 |
Company-defined net working capital (AUD Mn) | — | — | 126.0 | 94.1 |
NTA per share (A cents) | — | — | -3.30 | -8.59 |
Cash Flow
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
Operating cash flow (AUD Mn) | 44.5 | -13.4 | 29.1 |
Capex – PP&E (AUD Mn) | 6.8 | 11.7 | 30.6 |
Capex – intangibles (AUD Mn) | 12.5 | 5.2 | 2.6 |
Free cash flow (OCF less capex, AUD Mn) | 25.1 | -30.3 | -4.1 |
Lease principal repaid (AUD Mn) | 8.0 | 11.0 | 13.3 |
Acquisitions, net of cash (AUD Mn) | 25.1 | 0.5 | 51.4 |
Dividends paid (AUD Mn) | 12.6 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY24 | FY25 | FY26 |
|---|---|---|---|
ROE (% ; NPAT / average equity) | 5.3 | 6.6 | -5.1 |
ROA (% ; NPAT / average assets; FY24 end-period) | 0.7 | 1.7 | -1.2 |
ROIC (% ; statutory EBIT x 0.7 / (equity + net debt)) | 4.5 | 7.5 | 1.6 |
ROIC underlying (% ; (underlying EBITDA − D&A) x 0.7 / IC) | — | 8.6 | 7.2 |
Current ratio (x) | 0.96 | 0.98 | 0.88 |
Debt / equity (x ; borrowings only) | 0.67 | 0.72 | 1.04 |
Net debt / statutory EBITDA (x) | 3.97 | 2.45 | 5.59 |
Net debt / underlying EBITDA (x ; analyst) | — | 2.27 | 2.92 |
Net debt / underlying EBITDA (x ; company, incl. LTM of acquisitions) | 1.91 | 2.26 | 2.50 |
Interest coverage (x ; statutory EBIT / finance costs) | 1.86 | 1.77 | 0.38 |
Interest coverage underlying (x) | — | 1.97 | 1.70 |
Asset turnover (x) | 2.58 | 3.02 | 2.81 |
DSO (days ; trade receivables / revenue) | — | 34.6 | 36.5 |
DIO (days ; inventory / COGS) | — | 31.3 | 37.5 |
DPO (days ; trade & other payables / COGS) | — | 63.9 | 65.8 |
Cash conversion cycle (days) | — | 2.0 | 8.2 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY25 | FY26 |
|---|---|---|
Australia | 3,452.6 | 3,460.8 |
New Zealand | 60.0 | 59.6 |
Asia | 101.3 | 160.1 |
Total | 3,613.9 | 3,680.5 |
Growth / mix (%)
| Growth / mix (%) | FY25 | FY26 |
|---|---|---|
Australia growth (%) | — | 0.2 |
New Zealand growth (%) | — | -0.6 |
Asia growth (%) | 20.6 | 58.0 |
Australia share (%) | 95.5 | 94.0 |
New Zealand share (%) | 1.7 | 1.6 |
Asia share (%) | 2.8 | 4.3 |
Region non-current assets (AUD Mn)
| Region non-current assets (AUD Mn) | FY25 | FY26 |
|---|---|---|
Australia | 415.9 | 362.4 |
New Zealand | 32.6 | 27.8 |
Asia | 35.6 | 200.2 |
Share Price History
| Date | Price | Context | Source |
|---|---|---|---|
Jun 2024 | ≈0.36 implied |
| Baker McKenzie; calc. |
Dec 2025 (pre-receivership) | ≈0.25–0.26 | Shares had lost >50% since start of 2025 | Business News Australia |
17 Dec 2025 | 0.22–0.235 intraday | Infinity receivership | Press |
2 Jan 2026 | 0.215 | 2026 opening price | InvestSMART |
2026 high | 0.255 | — | InvestSMART |
24 Feb 2026 | 0.21 | Pre-1H26 results | Motley Fool |
26 Feb 2026 | 0.19 | Post-1H26 results | Motley Fool |
12 Mar 2026 | 0.17 | 1-year return −55.1%; 52-week high 0.45 | Simply Wall St |
7 Aug 2026 | 0.13 | 2026 low 0.125 | InvestSMART |
4 Sep 2026 | 0.135 | Latest verified; market cap ≈A$223m | InvestSMART |
Performance metric | Value | — | — |
2026 YTD to Aug 2026 (%) | -39.5 | — | — |
1-year to Mar 2026 (%) | -55.1 | — | — |
Since merger completion (Jun 2024 implied ~0.36 to 0.135, %) | -62.5 | — | — |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation (AUD Mn) | 223 | 1,655.3m shares |
Enterprise value ex-leases (AUD Mn) | 507 |
|
EV incl. leases and earn-outs (AUD Mn) | 644 |
|
EV / underlying EBITDA (x) | 6.6 | 644 / 97.2 (post-AASB 16 consistent) |
EV / underlying EBITDA ex-leases (x) | 5.2 | 507 / 97.2 |
EV / Sales (x) | 0.14 | 507 / 3680.5 |
P/E underlying (x) | 8.6 | 223 / 26.0 |
P/B (x) | 0.75 | 223 / 295.9 |
Dividends & Capital Returns
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
Dividend per PGC share (A cents) | 0 | 0 | 0 |
Dividends paid (AUD Mn; FY24 = CH2 pre-merger owners) | 12.6 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 |
Debt Facilities
| Facility | Limit | Drawn | Maturity | Pricing | Covenants |
|---|---|---|---|---|---|
Debtor Finance Facility (ScotPac) | A$325.0m (min. draw A$125m; limited by eligible receivables) | A$206.2m | 12 Jun 2028 (voluntary prepayment from 12 Jun 2027) | BBSY + 3.05% | Nil |
Asset Based Facility | A$75.0m | A$75.0m (fully drawn) | 12 Jun 2028 | BBSY + 3.05% | Nil |
Thailand trade finance | US$17m committed + US$10m uncommitted | US$10.0m (A$14.4m) | 180-day terms | Commercial | None; PGC guarantee up to US$10m |
NZ revolving credit | NZ$12.0m | A$9.8m (fully drawn) | Amortising from 13 months after draw | Commercial | Interest cover and leverage (complied) |
Hire purchase | A$3.0m | A$1.5m | Various | — | — |
American Express purchasing | A$8.0m | Nil | 35 days post statement | 1.45% fee | — |
Debt maturity (AUD Mn) | FY27 | FY28 | — | — | — |
Current borrowings (contractual/classification) | 222.6 | — | — | — | — |
Non-current borrowings | — | 85.2 | — | — | — |
Analyst Conclusions
Management guidance
No quantitative FY27 guidance (withheld due to "economic instability"); management expects mid-single-digit revenue growth, continued underlying organic revenue and earnings growth, ongoing supply-chain disruption, continued M&A, buyback commencement and a dividend review at 1H27. FY26 guidance was met on revenue and at the bottom of the range on underlying EBITDA.
Consensus
Consensus forecasts are not publicly disclosed in reviewed sources (the most recent aggregator view, Aug 2025, implied ~5% revenue growth).
Bull case
-
Earnings base is cleaner than the statutory loss suggests. Strip out the A$34.9m net Infinity charge and FY26 underlying EBITDA of A$97.2m grew 7.4% in constant currency; with Ramsay gone, Brisbane DC live and a full year of Haju (A$28.8m annualised revenue uplift at high margin), FY27 underlying EBITDA could plausibly exceed A$105m.
-
Mix shift toward Asia and specialty raises quality. Asia already earns more statutory EBITDA (A$32.0m) than ANZ; each A$100m of Asian revenue at ~42% gross margin is worth far more than wholesale revenue at ~6%.
-
Valuation is undemanding. At ~0.75x book, ~8.6x underlying earnings and ~5–6.6x EV/EBITDA, small improvements in cash conversion, a successful buyback and any Infinity recovery above A$9.3m could re-rate the stock.
Bear case
-
Leverage plus thin margins equal fragility. Net debt of A$284m plus A$81m of leases and A$56m of earn-outs against A$97m of underlying EBITDA; statutory interest cover of 0.38x in FY26; another credit event comparable to Infinity would erase a year's earnings.
-
Wholesale is structurally disadvantaged. The group lost Ramsay on price, has an independent-pharmacy customer base under consolidation pressure, and competes against peers with 3–4x the scale and far stronger balance sheets.
-
Governance and disclosure quality discount is warranted. One independent director, a qualified FY25 audit, two CFO exits, discretionary bonuses despite missed gateways, negative NTA and a debt-funded acquisition spree with large provisional goodwill all justify a persistent discount.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing |
|---|---|
| Infinity store-sale completions and final recovery vs A$9.3m booked | Sep–Dec 2026 |
| FY26 Annual Report: audit opinion (clean vs qualified), FY26 KMP remuneration | Released 29 Sep 2026 |
| 2026 AGM: remuneration vote (first-strike risk), trading update | Expected Nov 2026 |
| CFO appointment | Open |
| Buyback launch and size | FY27 |
| 1H27 results: dividend decision, net working capital, leverage trajectory | Feb 2027 |
| ADF contract ramp-up; NZ wholesale launch; PMC ANZ commencement | 1H FY27 |
| Somnotec Thailand completion | FY27 |
| Earn-out payments (A$22.3m current) | FY27 |
| Facility optionality (prepayment window opens 12 Jun 2027) and refinancing ahead of Jun 2028 maturity | 2,027 |
| Sydney warehouse decision | FY27 for FY28 go-live |
Analyst verdict
ParagonCare is a strategically coherent but financially stretched mid-cap distributor whose equity has been re-priced to reflect execution and credit risk rather than its underlying earnings power. The 2024 reverse merger achieved its operational objectives: the three businesses are on one ERP, synergies were delivered, low-margin contracts have been pruned and gross margin has risen from roughly 6% to 9.4%. Underlying EBITDA has been stable at A$95–97m for two years, and the Asian platform is now genuinely material, producing more statutory EBITDA in FY26 than the far larger ANZ business.
The problem is the conversion of that EBITDA into shareholder value. Finance costs absorb more than a third of underlying EBITDA, depreciation is rising with new warehouses and acquired intangibles, contingent consideration has ballooned, tangible equity is negative, and the Infinity collapse exposed weak credit controls and a board without the independent oversight one would expect of a A$3.7bn-revenue business. Revenue growth in ANZ is near zero once lost contracts are included, and management has declined to give earnings guidance.
At roughly A$0.135, the market values the company at about 0.75x book and about 6.6x fully-loaded EV/EBITDA, which already discounts a great deal. The near-term path to a re-rating requires three things: a clean FY26 audit opinion and an Infinity recovery at or above the booked A$9.3m; demonstrable free cash flow in FY27 (positive after capex, leases and earn-outs) that allows leverage to fall below 2.5x without asset sales; and governance reform, most obviously the appointment of additional independent directors and a permanent CFO. Absent those, the founder-controlled register and limited float make the stock a value trap rather than a value opportunity.
Overall stance: speculative, catalyst-dependent. Constructive only for investors who can underwrite balance-sheet risk and governance concentration; cautious for everyone else until FY27 cash generation is evidenced.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background / education | Independence | Shareholding |
|---|---|---|---|---|---|
Peter Lacaze | Non-Executive Chair; Chair, Nomination & Remuneration Committee; member, Audit & Risk Committee | PGC board since Jun 2024; CH2 Chair since Dec 2015 | BCom, MBA, MAICD, FCPA; CH2 CEO 2006–08; career across healthcare and travel | Not independent (≈28.5% holder) | 471,762,036 shares (FY25 AR) |
David Collins | Executive Director (was CEO & MD to 30 Jun 2025; MD to 28 Feb 2026) | PGC board since Jun 2024; CH2 since 2005 | BBus; CH2 CFO from 2005, MD 2008–14 and from 2015; former CFO Greencross Health (Auckland) | Not independent (executive; ≈28.5% holder) | 471,762,036 shares |
Carmen Riley | CEO (from 1 Jul 2025) and Managing Director (from 1 Mar 2026) | CH2 board from Jul 2019; ~15+ years at CH2 | BCom, CPA, GAICD; former CEO of PQ Lifestyles (Intouch); FMCG supply-chain, finance and project management background | Not independent (executive) | 438,888 shares and 4,462,144 performance rights (FY25 AR); 5,996,911 shares issued 3 Jul 2026 |
John Walstab | Non-Executive Director (from 1 Apr 2025) | PGC board since Feb 2022 | Founder and former MD/CEO of Quantum Health Group; PGC MD 2023–Jun 2024; ex-MD ATL (Philips Medical Systems ANZ) | Not independent (former executive within 3 years; ≈8.7% holder) | 144,591,185 shares (FY25 AR) |
Peter Egglestone | Independent Non-Executive Director; Chair, Audit & Risk Committee | Since 20 Mar 2025 | 25+ years finance/commercial leadership; former CEO of a payments facilitator; former C-suite at Journey Beyond | Independent | 100,000 (FY25); bought 200,000 in Jun 2026 |
Former: Alan McCarthy | NED | Feb 2022 – 31 Mar 2025 | Former MD Philips ANZ, VP Asia Pacific CareFusion | Was independent | — |
Executive Leadership Team
| Name | Title | Tenure / notes | Source |
|---|---|---|---|
Carmen Riley | CEO & Managing Director | CEO 1 Jul 2025; MD 1 Mar 2026; 12-month notice | ASX 25 Feb 2026 |
David Collins | Executive Director | Transitioned from MD 1 Mar 2026 | ASX 25 Feb 2026 |
Chief Financial Officer | — | ASX 15 Oct 2025 | — |
Michael Sapountzis | Company Secretary (Vistra) | Since 22 Nov 2024 | FY25 AR |
Investor relations | Howard Marks, Automic Group | — | FY26 Appendix 4E |
Directors' Remuneration
| Name | Salary & fees | Bonus | Non-monetary | Termination | Super | LSL | Share-based | Total |
|---|---|---|---|---|---|---|---|---|
Peter Lacaze (Chair) | 134,529 | 0 | 0 | 0 | 15,471 | 0 | 0 | 150,000 |
David Collins (CEO/MD) | 780,364 | 408,250 | 82,501 | 0 | 30,000 | 12,861 | 0 | 1,313,976 |
Carmen Riley (COO/ED) | 559,546 | 0 | 0 | 0 | 30,000 | 16,630 | 1,108,119 | 1,714,295 |
John Walstab (exec to 31 Mar 2025) | 397,840 | 220,267 | 50,000 | 220,017 | 29,932 | 6,563 | 0 | 924,619 |
John Walstab (NED from 1 Apr 2025) | 16,816 | 0 | 0 | 0 | 1,934 | 0 | 0 | 18,750 |
Peter Egglestone (NED) | 18,886 | 0 | 0 | 0 | 2,172 | 0 | 0 | 21,058 |
Alan McCarthy (NED) | 56,250 | 0 | 0 | 0 | 0 | 0 | 0 | 56,250 |
Marcus Crowe (CFO, from 1 Mar 2025) | 159,127 | 0 | 0 | 0 | 11,509 | 2,334 | 0 | 172,969 |
Michael Peters (CFO, to 6 Sep 2024) | 86,789 | 0 | 0 | 0 | 7,483 | 0 | 0 | 94,272 |
Total KMP | 2,210,147 | 628,517 | 132,501 | 220,017 | 128,501 | 38,388 | 1,108,119 | 4,466,189 |
Major Shareholders
| Holder | Shares | % of 1,655.3m | Source |
|---|---|---|---|
Peter Lacaze (and related) | 471,762,036 | 28.5 | FY25 AR |
David Collins (and related) | 471,762,036 | 28.5 | FY25 AR |
John Walstab (and related) | 144,591,185 | 8.7 | FY25 AR |
Carmen Riley | ≈6.4m (438,888 + 5,996,911 issued Jul 2026) | 0.4 | FY25 AR; Motley Fool director dealings |
Peter Egglestone | ≈300,000 | 0.02 | FY25 AR; Jun 2026 trade |
Competitive Landscape
Competitor Detail
| Channel | Competitor | Type / positioning | Comparative scale (where verified) |
|---|---|---|---|
ANZ pharmaceutical wholesale | EBOS Group (Symbion, NZX/ASX: EBO) | Largest ANZ healthcare distributor; CSO wholesaler | FY26 revenue A$13,487m; underlying EBITDA A$614m (4.6%); Healthcare segment A$12,580m |
ANZ pharmaceutical wholesale/retail | Sigma Healthcare (ASX: SIG, incl. Chemist Warehouse) | Vertically integrated wholesaler-franchisor | FY26 revenue A$10.8bn; normalised EBIT A$1,090m (10.1%) |
ANZ pharmaceutical wholesale | Wesfarmers Health (API / Priceline) | CSO wholesaler and banner owner; Infinity's primary wholesaler | — |
ANZ medical consumables | Medline, Cardinal Health, Bunzl Healthcare, Independence Australia, Team Medical Supplies | Global/regional consumables distributors | — |
ANZ medtech agencies | Device Technologies, LifeHealthcare (private), and OEMs going direct (Medtronic, Stryker, J&J MedTech, Zeiss, etc.) | Specialty distributors and manufacturers | — |
Asia medtech/healthcare distribution | DKSH (SIX: DKSH), Zuellig Pharma | Pan-Asian market-expansion service providers | — |
Contract logistics | DHL Supply Chain, EBOS, Sigma, Movianto-type 3PLs | Healthcare 3PL/4PL | — |
Blood-bank reagents | Bio-Rad, Grifols, Ortho Clinical Diagnostics (QuidelOrtho), Immucor/Werfen | Global IVD manufacturers | — |
Complementary medicines distribution | Pharmacy wholesalers and direct brand distribution | — | — |
Peer Comparison FY2026
| Metric | ParagonCare | EBOS Group | Sigma Healthcare |
|---|---|---|---|
Revenue | 3,680.5 | 13,487 | 10,800 |
Revenue growth (%) | 1.8 | 9.9 | 15.5 |
Underlying EBITDA | 97.2 | 614 | — |
Underlying EBITDA margin (%) | 2.6 | 4.6 | — |
Normalised EBIT | 59.9 | 465.8 | 1,090 |
Normalised EBIT margin (%) | 1.6 | 3.5 | 10.1 |
Net debt / EBITDA (x, company basis) | 2.5 | 2.1 | 0.57 |



